Verrica Pharmaceuticals Inc.
VRCADrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
15dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How VRCA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Part 1: VP-315 3 Day Dosing/Week | Phase 2 | Basal Cell Carcinoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Verrica Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Verrica Pharmaceuticals Inc.'s (VRCA) pipeline across Phase 2. Its lead program is Part 1: VP-315 3 Day Dosing/Week (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Verrica Pharmaceuticals Inc.'s next FDA catalyst?→
Verrica Pharmaceuticals Inc.'s (VRCA) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VRCA biotech catalysts?→
Add VRCA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Verrica Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.